Climb Bio, Inc.

For the period ended Dec 31, 2024. Filed Mar 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 25, 2025

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	As of December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$87,229	$93,112
Short-term marketable securities	63,690	13,686
Prepaid expenses and other current assets	3,953	3,457
Total current assets	$154,872	$110,255
Operating lease right-of-use assets	490	199
Long-term marketable securities	61,610	—
Other long-term assets	215	15
Total assets	$217,187	$110,469
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$705	$66
Accrued expenses and other current liabilities	4,069	2,433
Operating lease liabilities	157	334
Total current liabilities	$4,931	$2,833
Operating lease liabilities, net of current portion	375	15
Other long-term liabilities	—	22
Total liabilities	$5,306	$2,870
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 67,255,434 and 27,699,446 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	7	3
Additional paid-in capital	441,727	263,577
Accumulated other comprehensive income (loss)	23	(2)
Accumulated deficit	(229,876)	(155,979)
Total stockholders’ equity	$211,881	$107,599
Total liabilities and stockholders’ equity	$217,187	$110,469

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.